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FOREWORD
Evidence-Based Resource Guide 
Series Overview
The Substance Abuse and Mental Health Services 
Administration (SAMHSA), and specifically, its National 
Mental Health and Substance Use Policy Laboratory 
(Policy Laboratory), is pleased to fulfill the charge of 
the 21st Century Cures Act to disseminate information 
on evidence-based practices and service delivery models 
to prevent substance misuse and help individuals with 
substance use disorders (SUD), serious mental illnesses 
(SMI), and serious emotional disturbances (SED) get the 
treatment and support they need.
Treatment and recovery for SUD, SMI, and SED can 
vary based on geographic, socio-economic, cultural, 
gender, race, ethnicity, and age-related factors. This 
can complicate evaluating the effectiveness of services, 
treatments, and supports. Despite these variations, 
however, there is substantial evidence to inform the 
types of resources that can help reduce substance use, 
lessen symptoms of mental illness, and improve quality 
of life. 
The Evidence-Based Resource Guide Series is a 
comprehensive set of modules with resources to improve 
health outcomes for people at risk for, experiencing, or 
recovering from mental and/or substance use disorders. 
It is designed for clinicians, administrators, community 
leaders, and others considering an intervention for 
their organization, community, client, or loved one. A 
priority topic for SAMHSA is encouraging treatment 
practices that improve outcomes for youth and young 
adults with SED/SMI who also have or are at risk for 
co-occurring substance misuse or SUD. This guide 
reviews the literature and science, examines evidence-
based practices, determines key components of those 
treatment practices, identifies challenges and strategies 
for implementation, and discusses evaluation of 
implemented evidence-based practices.
A Note on Terminology
It is important to understand that SED and 
SMI are not diagnostic categories; they 
are broad encompassing terms used in 
public health to refer to the range of various 
diagnosed mental illnesses in youth and 
young adults, respectively, which significantly 
impair functioning. Disorders such as major 
depression, bipolar, and post-traumatic stress 
disorder fall under the larger umbrella of SED/
SMI when they significantly impair functioning. 
While substance use disorders are not 
considered part of the SED/SMI categories, all 
these disorders, are typically formally diagnosed 
according to DSM-5 criterion.
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Expert panels of federal, state, and non-governmental 
participants provide input for each guide in this series. 
The panels include accomplished scientists, researchers, 
service providers, community administrators, federal and 
state policy makers, and people with lived experience. 
Members provide input based on their knowledge of 
healthcare systems, implementation strategies, evidence-
based practices, provision of services, and policies that 
foster change. 
Research shows that implementing evidence-based 
practices requires a comprehensive, multi-pronged 
approach. This guide is one piece of an overall 
approach to implement and sustain change. Readers are 
encouraged to visit the SAMHSA website for additional 
tools and technical assistance opportunities.
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Content of the Guide
This guide contains a foreword and five chapters. The chapters stand alone 
and do not need to be read in order. Each chapter is designed to be brief and 
accessible to healthcare clinicians, healthcare system administrators, community 
members, policy makers, and others working to meet the needs of individuals 
at risk for, experiencing, or recovering from mental and/or substance use 
disorders. The goal of this guide is to review the literature on treating substance 
misuse and SUD in youth and young adults with SED/SMI, distill the research 
into recommendations for practice, and provide examples of how clinicians use 
these treatment practices in their programs.
FW Evidence-Based Resource Guide Series Overview
Introduction to the series.
1 Issue Brief
Overview of current approaches and challenges to addressing 
SED/SMI and co-occurring substance misuse or SUD among 
youth and young adults.
2 What Research Tells Us
Current evidence on effectiveness of the following treatment 
practices included in the guide to address SED/SMI and co-
occurring substance misuse or SUD in youth and young adults: 
 ● Cognitive behavioral therapy (CBT)
 ● Multidimensional family therapy (MDFT)
 ● Pharmacotherapy 
3 Guidance for Selecting and Implementing 
Evidence-based Practices 
Practical information to consider when selecting and 
implementing treatment practices and programs to address 
SED/SMI and co-occurring substance misuse or SUD in youth 
and young adults.
4 Examples of Treatment Programs
Descriptions of programs that use treatment practices from 
Chapter 2 to address SED/SMI and co-occurring substance 
misuse or SUD in youth and young adults. 
5 Resources for Evaluation and Quality Improvement
Guidance and resources for implementing best practices, 
monitoring outcomes, and improving quality.
FOCUS OF THE GUIDE
Treatment services for youth and 
young adults living with SED/SMI 
who may have or be at risk for 
co-occurring SUD have improved 
in recent years. However, an 
opportunity exists to broaden the 
availability and utilization of these 
services. For this reason, knowledge 
and implementation of interventions 
to improve engagement and 
treatment in clinical settings are 
essential. 
This guide presents three evidence-
based practices that engage and 
improve outcomes for youth and 
young adults with co-occurring 
SED/SMI and substance misuse 
or SUD. These approaches will 
assist clinicians, behavioral health 
organizations, primary care providers, 
schools, insurers, transformation 
experts, and policy makers to 
understand, select, and implement 
evidence-based interventions that 
support youth and young adult mental 
health. These include psychosocial 
interventions, family behavioral 
therapy, medication, proactive 
outreach, and use of web-based and 
other technologies. 
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The framework below provides an overview of the treatment practices and the outcomes included in the 
guide. The guide addresses co-occurring SED/SMI and substance misuse or SUD in youth and young adults 
and treatment practices that have been evaluated for this population. This guide will not specifically address 
the needs of or all relevant treatment practices for individuals with all disorders that fall under the SED/SMI 
categories, including schizophrenia and other mental disorders. The review of these interventions in Chapter 2 
includes specific outcomes, clinician types, and delivery settings.
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and emotional changes 
occur during the teen 
years and transition into 
adulthood. Mental health 
and substance misuse 
issues commonly first 
emerge at this time.2
This chapter presents an overview of the current 
understanding of common mental illnesses co-occurring 
with substance misuse or substance use disorders (SUD), 
with a particular emphasis on youth with SED and young 
adults with SMI.
Healthy and unhealthy mental, emotional, and behavioral 
development are influenced by youth and young adults’ 
social and physical environments. These influences include 
physical, social, and other experiences, an individual’s 
sleep, nutrition, and physical activity, peer behavior, 
parental behavior, and societal characteristics (e.g., 
poverty, law- and policy-driven factors, systemic racism, 
and discrimination).1 Many physical, developmental, 
social, and emotional changes occur during the teen years 
and transition into adulthood. Mental health and substance 
misuse issues commonly first emerge at this time.2
Family, friends, or clinicians may confuse mental health 
and substance misuse symptoms for the angst, social 
stressors, and strong emotions that commonly occur with 
teens. Additionally, multiple clinical, administrative, 
financial, and policy barriers often lead to under 
diagnosis and inadequate treatment of mental health and 
substance use issues during this life stage.2 
Among youth and young adults in need of mental 
health services, co-occurring substance misuse is 
highly prevalent. This is particularly evident in special 
populations like youth in juvenile detention, youth living in 
rural communities, and youth in residential or foster care.3-6
The timing of mental illness onset with SUD varies.2 
For some youth and young adults, the SED/SMI may 
precede the SUD; for other individuals, the reverse can 
occur. These disorders may also develop during the same 
period. SED/SMI is associated with an increased risk of 
SUD and substance misuse, and SUD can contribute to 
the development of mental illness. 
Risk and Protective Factors
Protective factors are characteristics 
associated with a higher likelihood of positive 
outcomes or those that reduce a risk factor’s 
impact. Protective factors may be seen as 
positive countering events or actions. 
•	 Individual-level protective factors 
might include positive self-image, self-
control, or social competence.
Risk factors are characteristics at the 
biological, psychological, family, community, or 
cultural levels that precede and are associated 
with a higher likelihood of negative outcomes. 
•	 Individual-level risk factors may 
include a person’s genetic composition 
or prenatal exposure to alcohol. 
Some risk and protective factors, such as 
income level, peer group, trauma exposure, 
and employment status, may change over time, 
while others can remain constant.7 
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The symptom, severity, age of onset, and other 
characteristics differ based on an individual’s risk, 
protective factors, and other influences, as described 
above. Common risk factors for development of mental 
illnesses and substance use disorders in youth and young 
adults include abuse and neglect, death of a loved one, 
and community violence, among others, which can lead 
to serious mental and physical health concerns. 
While most youth and young adults return to normal 
functioning after stressful events, others may show 
symptoms related to trauma.8-9 Trauma refers to experiences 
that cause intense physical and psychological stress 
reactions.10 More than 66 percent of youth in the United 
States experience a traumatic event or circumstances by 16 
years of age8 and many children experience chronic trauma.9
Adverse childhood experiences (ACEs), or potentially 
traumatic events experienced before the age of 18, can 
have long-term impacts on youth who experience them.11 
ACEs include growing up in a household with substance 
misuse and/or mental health problems; instability due 
to parental separation; and household members being in 
jail or prison.11 Youth who experience ACEs, especially 
those who experience multiple ACEs, are more likely to 
suffer harmful long-term consequences, such as major 
depressive disorder, SUD, or physical conditions like 
obesity and high blood pressure when not met with an 
understanding and trauma-appropriate response from 
adults.12
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In particular, youth and young adults with SED/SMI 
vary in symptom type, severity, and history of trauma.13 
Clinicians differ in their approach to identifying and 
treating individuals with co-occurring disorders, because 
the factors that lead individuals to seek care are complex 
and vary by individual.  
Screening and comprehensive assessments are essential 
to identify youth and young adults at risk for or 
struggling with SUD, mental illnesses, or co-occurring 
conditions. Health service providers, juvenile justice 
workers, educators, and other professionals who work 
with youth and young adults should screen and, as 
appropriate, refer for further assessment. 
Universal screening for mental and substance use 
disorders should be a standard part of any primary care 
practice. Additionally, providers that primarily treat youth 
and young adults with SED or SMI should be equipped to 
screen and assess for co-occurring substance misuse and 
SUD. When first working with a potential client, primary 
care, mental health, and substance use providers can 
conduct an intake screening tools such as the following:
Screening Tools:
•	 Generalized Anxiety Disorder (GAD-7) 
•	 Major Depressive Disorder Module of the 





•	 Substance Abuse Subtle Screening Inventory 
(SASSI) 
•	 Comprehensive Adolescent Severity Inventory 
(CASI)
•	 Diagnostic Interview Schedule for Children 
(DISC)
•	 Drug Use Screening Inventory (revised) 
(DUSI-R)
•	 Global Appraisal of Individual Needs (GAIN)
SAMHSA’s Treatment Improvement Protocol 31: 
Screening and Assessing Adolescents for Substance Use 
Disorders provides detailed information on screening for 
substance use and co-occurring conditions. 
For maximum benefit, each individual’s treatment plan 
must be specific to their circumstances and person-
centered.2 For example, multiple individuals with the 
same disorder profile may require different treatment 
depending on contributing factors, order of onset, and 
relative severity of their symptoms—all of which can 
complicate treatment. 
Youth and young adults with co-occurring disorders have 
unique challenges, risks, and childhood experiences. 
Few programs exist that address their specific needs. 
Without evidence-based strategies, services, and 
programs to identify and treat co-occurring SUD in 
youth and young adults with SED or SMI, they may 
face an increased risk of serious medical, legal, and 
interpersonal problems.
Prevalence and Other Data
It is common to experiment with alcohol and illicit 
substances during the teen years. By late adolescence, 
more than 75 percent of youth in the United States 
have consumed alcohol, and over 40 percent have used 
an illicit substance at least once.14 More critically, 11 
percent of youth (ages 13 and 14) experience SUD and 
15 to 16 percent of older youth (ages 17 and 18) have 
behavior that meets the criteria for alcohol or drug 
misuse.14 
SAMHSA. (2020). Key substance use and mental health indicators 
in the United States: Results from the 2019 National Survey on Drug 
Use and Health. https://www.samhsa.gov/data/sites/default/files/
reports/rpt29393/2019NSDUHFFRPDFWHTML/2019NSDUHFFR1PD-
FW090120.pdf. 
Williams, N.J., Scott, L., & Aarons, G.A. (2018). Prevalence of Serious 
Emotional Disturbance Among U.S. Children: A Meta-Analysis. Psychi-
atric Services, 69(1), 32-40. https://doi.org/10.1176/appi.ps.201700145
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In addition, many youth and young adults experience 
symptoms of a mental illness that may not be disabling 
enough to qualify as a full SED or SMI.15-16 For example, 
one national survey notes high rates of anxiety disorders 
that do not necessarily meet criteria for a SED, especially 
among females, older youth, and ethnic minorities.17
Approximately 2 percent of individuals aged 12 to 
17 met the criteria for co-occurring major depressive 
episode and SUD.16 Among young adults, three percent 
met the criteria for co-occurring SMI and SUD. As 
with youth, young adults with SMI reported using illicit 
substances at higher rates than those without SMI.16 
Youth and young adults have increased risk of SUD 
associated with some disorders, including, but not 
limited to, anxiety disorders,18-19 depressive disorders,18,20 
and bipolar disorder.21 For example, the rate of illicit 
drug use in the prior year was higher among youth with a 
recent history of a major depressive episode (33 percent) 
than those without (14 percent). Additionally, ADHD 
was reported for 38 percent of both girls and boys.22 
Impact of the Problem
Individuals with co-occurring disorders experience greater 
functional impairment, with greater negative outcomes, 
than people diagnosed with a single disorder.23 Moreover, 
youth and young adults specifically diagnosed with co-
occurring SED/SMI and SUD are at increased risk of 
suicidal ideation and attempts,24 failure to graduate high 
school on time,25 and early pregnancy26 compared to 
others without a disorder or those with one. 
Data on the prevalence of co-occurring disorders in the 
juvenile justice system is limited. However, estimates 
suggest that youth already in contact with the system have 
much higher prevalence of co-occurring SED and SUD 
than youth overall.27 Roughly 62 percent of individuals 
in the juvenile justice system meet criteria for at least one 
mental disorder. Among these individuals, 61 percent had 
co-occurring SUD.28
Similarly, youth and young adults who experience 
homelessness have a much higher prevalence of mental 
disorders (e.g., anxiety disorder, panic disorder, major 
depression, bipolar disorder, schizophrenia, and post-
traumatic stress disorder) and SUD than youth and young 
adults who have stable homes.29
Barriers and Facilitators 
to Treatment
According to the 2019 National Survey on Drug Use 
and Health, 17 percent of individuals aged 12 to 17 
access mental health services in specialty settings and 
18 percent in non-specialty settings.16 Specialty settings 
include inpatient, residential, and outpatient mental health 
settings. Non-specialty settings include outpatient primary 
health care, educational, child welfare, and juvenile justice 
settings. Of those youth who received mental health 
services in non-specialty settings, 85 percent received the 
services in a school setting. 16 
When youth and young adults with SED/SMI and co-
occurring substance misuse or SUD receive treatment, they 
may access care in either the mental health system or the 
substance use treatment system.2 They may move from 
one system to the other or access different levels of care or 
different clinicians throughout the course of their treatment. 
This piecemeal approach to treatment often results in 
inconsistent delivery of care and less than optimal outcomes.2 
Source: Merikangas, K.R., He, J., Burstein, M., Swanson, S. A., 
Avenevoli, S., Cui, L., Benjet, C., Georgiades, K. & Swendsen, J. 
(2010). Lifetime prevalence of mental disorders in US adolescents: 
results from the National Comorbidity Survey Replication–Adolescent 
Supplement (NCS-A). Journal of the American Academy of Child & 
Adolescent Psychiatry, 49(10), 980-989. https://doi.org/10.1016/j.
jaac.2010.05.017
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Youth and young adults with co-occurring SED/SMI 
and SUD require treatment that addresses the whole 
person. Such person-centered services may include 
psychosocial interventions, family behavioral therapy, 
medication, proactive outreach, and use of specialized 
applications that can assist or provide an intervention 
and track symptoms. Integrated or combined treatment—
services that treat both SED/SMI and substance misuse 
or SUD—lead to better long-term outcomes.30 
Youth and young adults experiencing co-occurring 
disorders commonly face difficulties accessing 
integrated services designed to assess and treat their 
needs. This is due to:2
•	 Lack of access to health insurance or adequate 
insurance benefits.
•	 Fragmented or uncoordinated care, especially 
for youth and young adults in foster, juvenile 
justice, or residential settings, or those 
experiencing homelessness.
•	 Limited cross training and education for mental 
health and substance use professionals.
•	 Separate and geographically distinct SED/SMI 
and SUD treatment systems.
•	 Different and separate financing and 
reimbursement policies for each treatment 
option. 
These challenges persist across the United States and 
are particularly prominent in settings treating vulnerable 
populations. However, progress has been made. Exam-
ples include:2
•	 Increased integration of effective and evidence-
based behavioral health services in primary 
care and school settings, where youth access 
treatment and clinical services most often.
•	 Greater access to telehealth services. 
•	 Expanded capacity to identify and treat co-
occurring issues through more educational. 
As research has expanded what we know about SED, 
SMI, and co-occurring substance misuse and SUD, 
implementation of systematic and integrated approaches 
for this population are critical to increase the availability 
and access of services.1
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This chapter provides an overview of three treatment 
practices for co-occurring serious emotional disturbances 
(SED) and serious mental illnesses (SMI) and substance 
misuse or substance use disorders (SUD) in youth and 
young adults:
•	 Cognitive Behavioral Therapy (CBT)
•	 Multidimensional Family Therapy (MDFT)
•	 Pharmacotherapy 
Co-occurring conditions affect an individual’s physical and 
mental health. It is also a larger public health problem that 
can have negative impacts on families and communities. 
Literature around these treatment practices is often 
inconsistent, making identification of the most effective 
treatment methods challenging. Through a literature review 
and consensus from technical experts (see Appendix), 
authors identified three practices used to treat co-occurring 
SED/SMI and SUD in youth and young adults. Based on 
a comprehensive review of the available evidence, each 
selected treatment practice received a rating. 
Screening for SED/SMI and SUD using a 
standardized tool helps providers identify youth 
and young adults who may be at risk for co-
occurring disorders and implement appropriate 
care plans. A comprehensive assessment and 
history of a client’s mental function, substance 
use behavior, trauma, health history, and home 
life typically follows a positive screen. This 
should be completed using a structured or semi-
structured approach and the results can assist 
providers in determining appropriate next steps 
and tailoring specific treatments to meet the 
client’s needs.
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To be considered for inclusion in this guide, eligible 
treatment practices had to meet the following criteria: 
•	 Be clearly defined and replicable. 
•	 Address target outcomes detailed in the 
Foreword of this guide.
•	 Be currently in use. 
•	 Have evidence of effectiveness.
•	 Have accessible resources for effective 
implementation.
Evidence Review and 
Rating
Authors completed a comprehensive review of 
published research for each selected treatment practice 
to determine its strength as an evidence-based practice. 
Eligible research studies had to:
•	 Employ a randomized or quasi-experimental 
design or 
•	 Be a single sample pre-post design or an 
epidemiological study with a strong counterfactual 
(i.e., a study that analyzes what would have 
happened in the absence of the intervention). 
Descriptive and implementation studies and meta-
analyses were not included in the review but 
were documented to provide context and identify 
implementation supports for the treatment practices.
Each eligible study was reviewed for evidence of 
improvements in psychiatric symptomatology and 
reductions in SUD or substance use behavior. In cases 
where studies did not specifically identify SED or SMI 
as the population of interest, results are noted as relevant 
to the treatment of co-occurring conditions generally. In 
addition, trained reviewers checked each study to ensure 
rigorous methodology, asking questions such as:
•	 Are experimental and comparison groups 
demographically equivalent, with the only 
difference being that participants in the 
experimental group received the intervention and 
those in the comparison group received treatment 
as usual or with no or minimal intervention?
•	 Was baseline equivalence established between 
the treatment and comparison groups on 
outcome measures?
•	 Were missing data addressed appropriately?
•	 Were outcome measures reliable, valid, and 
collected consistently from all participants?
Using these criteria, each study’s causal impact was 
assessed and given a rating of low, moderate, or high. Only 
randomized controlled trials, quasi-experimental designs, 
and epidemiological studies with a strong comparison were 
eligible to receive a high or moderate rating.
After all studies for a treatment practice were assessed 
and rated, the treatment practice was placed into one of 
three categories based on its causal evidence level.* 
Causal Impact: Evidence demonstrating that 
an intervention causes, or is responsible for, 
the outcome measured in the study’s sample 
population.
* See Appendix 2 for more information about the evidence review process.
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Cognitive behavioral therapy (CBT) provides a 
framework for teaching skills related to managing 
emotions, challenging negative thoughts, and problem 
solving.1 
CBT is a short-term, goal-oriented psychotherapy 
treatment that enables individuals with co-occurring 
SED/SMI and SUD to identify and understand their 
current problems, challenges, and experiences, and 
change their patterns of thinking or behaviors. Using 
the CBT approach, clinicians can prioritize both SED/
SMI and co-occurring SUD in setting treatment goals. 
CBT allows clinicians to use a consistent therapeutic 
approach to both disorders.2 Previous systematic reviews 
have noted that CBT has favorable results for youth with 
anxiety or depression.3-5
Integrated Cognitive Behavioral Therapy (I-CBT) 
applies the same CBT tenets to address SUD and co-
occurring suicidal ideation or post-traumatic stress.2 
I-CBT specifically explores the relationship between 
these co-occurring disorders, while allowing flexibility 
in treatment sessions to work on them in isolation or at 
the same time. Common components of traditional CBT 
sessions for standalone disorders are combined, when 
logical, to address co-occurring disorders. For instance, 
certain problem-solving skills used for SUD and trauma 
are the same, so clinicians can present the problem-
solving skills in the context of both disorders. The 
flexibility of this format allows for easy adaptation to 
the individual, their presenting problems, and treatment 
goals. 
This review included five studies: four studies that 
assessed CBT1, 6-8 and one study that examined I-CBT.2 
While all studies reported positive, significant results, 
the I-CBT study, being the only randomized-controlled 
trial, determined the rating of the overall CBT practice. 
All five studies were conducted in outpatient settings 
(community mental health centers and school-based 
health centers) with clients who have co-occurring 
substance misuse or SUD and mental disorders, including 
post-traumatic stress disorder (PTSD), major depressive 
disorder (MDD), and suicidal ideation.1-2, 6-8 The 
studies found that CBT was associated with reductions 
in substance use and improvements in depressive 
symptoms. CBT can also be combined with motivational 
enhancement therapy (MET) and pharmacotherapy, as 
discussed in a separate section in this chapter.
Typical Settings
Mental health clinicians implement CBT in a wide 
range of healthcare settings, from inpatient psychiatric 
rehabilitation to community outpatient programs.9 
Studies in the current evidence review were conducted in 
integrated outpatient settings in individual,6-8 group,8 and 
family6,8 formats.
Identification of Effective Treatment Practices for Select 
Mental Illnesses and Co-occurring Substance Use
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Demographic Groups
CBT is a widely used therapy, across genders, 
ages, races, and ethnicities.10 Studies included 
demographically diverse participants aged 11 to 20 
with SUD and co-occurring mental disorders, including 
PTSD, MDD, and suicidal ideation.
Clinician Types
Many clinicians, including those in health care, mental 
health care, and juvenile justice settings, implement 
the core tenets of CBT. For co-occurring SED/SMI and 
substance misuse or SUD in youth and young adults, 
CBT is implemented by a variety of licensed behavioral 
health professionals. In the studies included in this 
review, master’s level and PhD-level clinicians, as well 
as psychiatrists, delivered the interventions.
Intensity and Duration of Treatment 
CBT is typically customized to the needs of each 
individual. Most people who seek CBT for co-occurring 
SED/SMI and SUD receive individual, weekly, 
60-minute counseling sessions.11 In reviewed research 
studies, the total treatment ranged from 3 months to 12 
months of weekly or twice-monthly sessions in both 
group and individual formats. 
OUTCOMES ASSOCIATED  
WITH CBT
Studies have demonstrated that use of CBT 
with youth and young adults with co-occurring 
mental disorders and SUD was associated with 
significant reductions at follow-up in: 
•	 Frequency of marijuana use6-7
•	 Frequency of general substance use1, 6-7
•	 Severity of PTSD symptoms7-8
•	 Severity of depressive symptoms6,8
•	 Frequency of trauma-associated 
cognitions7
The time between treatment and follow-up 
ranged between 0 and 9 months.
Outcomes Associated with I-CBT
One study demonstrated that use of I-CBT with 
youth and young adults with co-occurring SUD and 
suicidal thoughts and behaviors was associated 
with reductions at 6-month follow-up in:2
•	 Frequency of marijuana use 
•	 Level of functional impairment
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Family-based therapies refer to a discipline within 
psychotherapy and counseling that engages an individual 
along with their family members (e.g., parents, siblings, 
and other caregivers) in therapeutic sessions and 
treatment planning. Family-based therapy recognizes 
that an individual’s symptom management, retention in 
treatment, and overall treatment response is shaped not 
only by individual-level factors (e.g., genetics, personal 
motivation) but also family-level factors (e.g., home 
environment, interpersonal relationships). 
These therapies encompass numerous therapeutic 
schools of thought and individual treatment models, 
including, but not limited, to MDFT. MDFT is a 
manualized, family-based approach to treatment of 
youth substance misuse and SUD, concurrent substance 
use, and co-occurring mental health and behavioral 
problems.12-13 
Three randomized control trials (RCTs) have shown 
effectiveness of MDFT for youth with varying 
severity and type of SUD, but who do not have co-
occurring mental illness.14-16 Another  RCT showed 
effectiveness for youth with mental disorders.17 A prior 
systematic review, which included five RCTs assessing 
MDFT’s effectiveness in treating youth and young 
adults with substance misuse or SUD alone, found it 
slightly more effective in treating substance use than 
other treatments,18 which means that it is likely more 
effective than treatment as usual or no treatment. This 
review found MDFT affected on non-opioid drug and 
concurrent substance use reduction at 6- and 12-month 
follow-up, when compared to other treatments, though 
the differences were small.18
A second research review assessed MDFT’s 
effectiveness in reducing substance misuse, 
“delinquency, externalizing and internalizing 
psychopathology, and family malfunctioning” among 
adolescents with symptoms of substance misuse and/
or antisocial behavior (but without a diagnosed SED). 
It found significant improvement on each of these 
outcomes, despite overall effect size being similarly 
small.19 It also observed that adolescents with high 
severity substance misuse and disruptive behavior 
disorder benefited more from MDFT than those with less 
severe conditions.19 
A separate study evaluating MDFT14 conducted in 
outpatient settings with youth and young adults who 
have co-occurring mental disorders and substance 
misuse or SUD is included in this review. The study 
demonstrated significant reductions in substance use and 
negative mental health outcomes.
More Research is Needed: While MDFT has been 
found to effectively treat substance misuse and SUD 
and mental disorders, a limited number of studies have 
examined the effectiveness of MDFT for co-occurring 
SED/SMI and SUD in youth and young adults. 14 At a 
time when rates of SED/SMI and SUD in youth and 
young adults are rising, and few programs are available 
with well-established effectiveness, additional studies of 
MDFT’s effectiveness for youth and young adults with 
co-occurring SED/SMI and SUD would strengthen the 
body of evidence for its use in this population.
MDFT “integrates the clinical and theoretical 
traditions of developmental psychology and 
psychopathology, the ecological perspective, and 
family therapy…[and]… uses research-derived 
knowledge about risk and protective factors for 
adolescent drug and related problems as the basis 
for assessment and intervention in four domains:
1. [Youth], as an individual and as a member 
of a family or peer group, 
2. Parent, both as an individual adult and in 
his or her role as mother or father, 
3. Family environment and the family 
relationships, as evidenced by family 
transactional patterns, and 
4. Extrafamilial sources of positive and 
negative influence.”14
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Typical Settings
Family-based therapy can be conducted in both 
residential (e.g., inpatient, juvenile justice), home, and 
community-based settings. MDFT was developed for use 
in all setting types.20 The reviewed study was conducted 
in a community-based setting.
Demographic Groups
Family-based therapies engage family members and 
caregivers of all ages and backgrounds in the therapeutic 
process of the client. The individual around whom the 
treatment is organized is typically a youth, adolescent, 
or young adult, though specific treatment models and 
their applications may vary. MDFT, for example, was 
developed for youth and young adults. 
In the reviewed study, the sample population was dually 
diagnosed at intervention outset. The MDFT study 
sample was majority male and non-White Hispanic.17 
Individuals were excluded from participation in the 
study if they did not have a family member or caregiver 
willing to participate in the intervention, had active 
psychosis or suicidal ideation, or had limited cognition.
Clinician Types
A variety of mental health clinicians, including 
psychiatrists, psychologists, counselors, and social 
workers, can facilitate family-based therapies. MDFT 
clinicians must possess or be working toward a master’s 
degree in a clinical field; further, they must complete an 
MDFT training and coaching certification program for 
full credentialing.21 
In this review’s study, master’s level trained mental health 
clinicians served as the primary treatment clinicians.
Intensity and Duration of Treatment
Family-based therapies can vary significantly in 
treatment duration, intensity, and frequency. The length 
of treatment for MDFT is typically three to six months, 
with one to three hourly sessions per week.21 
OUTCOMES ASSOCIATED WITH MDFT
One study demonstrated that use of MDFT with youth who have a co-occurring psychiatric disorder and SUD 
was associated with significant reductions at follow-up of: 
•	 Problems associated with substance use
•	 Frequency of substance use in prior 30 days
•	 Internalization of mental health symptoms
Outcomes were assessed at 2 and 18 months post intervention.17
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Pharmacotherapy refers to medications approved by the 
Food and Drug Administration (FDA) to treat a youth’s 
or young adult’s SED/SMI. Pharmacotherapy may also 
include FDA-approved medications that address SUD, 
such as nicotine replacement and medications for opioid 
use disorder, depending on the individual’s age.
The FDA has approved several medications to treat youth 
and young adults with SED and SMI and others for youth 
and young adults with SUD. Other medications have been 
approved by the FDA to treat SMI in adults; not all of 
these are approved for use in youth. While FDA approval 
is required to confirm that a medication is safe and 
effective for a particular condition, not all medications that 
are used to treat children have been specifically studied 
in children. When FDA approval is not present, practice 
guidelines for pharmacotherapy in youth populations 
are informed by expert clinician and field consensus, 
often cited in medical academies such as the American 
Academy of Child & Adolescent Psychiatry (AACAP). 
Typically, medications are studied in adults to obtain FDA 
approval. Lack of FDA approval for use in children for 
a specific condition may mean that the pharmaceutical 
manufacturer did not conduct studies in children.  
Specific mood and anxiety diagnoses have medications 
approved for use in both youth and young adults; these 
include for depression (fluoxetine and escitalopram), 
general anxiety disorder (duloxetine), and obsessive 
compulsive disorder (OCD) (fluoxetine, clomipramine, 
fluvoxamine, sertraline). Different medications are 
approved for different phases of bipolar I disorder 
(acute mania, depression, mixed states, maintenance), 
including lithium, aripiprazole, risperidone, quetiapine, 
olanzapine (with and without fluoxetine), asenapine, 
and lurasidone. FDA-approved age ranges vary by 
medication. AACAP’s clinical practice guidelines and 
practice parameters provide guidance in the assessment 
and treatment of child and adolescent disorders.
SAMHSA’s First-Episode Psychosis and Co-Occurring 
Substance Use Disorders Guide describes effective 
treatment practices for individuals with these disorders. 
SAMHSA’s Treatment Improvement Protocol (TIP) 
63: Medications for Opioid Use Disorder documents 
three medications—buprenorphine, methadone, and 
naltrexone—that support improved health outcomes 
for individuals with opioid use disorder. The FDA has 
approved the use of buprenorphine for individuals aged 
16 and older and the use of methadone and naltrexone 
for individuals 18 and older. 
It is important providers address SED/SMI and SUD in 
treatment. Treating one condition will not treat the other. 
Pharmacotherapy and Psychotherapy
Medications for mental disorders provide significant 
relief for many people and help manage symptoms to 
the point where people can use other strategies to pursue 
recovery from the substance use disorder.31 For many 
people, the most effective behavioral health approach 
involves a combination of counseling and medication.32
Counseling and more specialized psychotherapies, 
including CBT and motivational enhancement therapy 
(MET) seek to change behaviors, thoughts, emotions, and 
how people see and understand situations.29-30 MET is a 
brief intervention designed to enhance an individual’s 
engagement in treatment, motivation to change, and 
self-efficacy by using a nonjudgmental approach of 
active listening, reflection, and evaluation of patient 
response.31 CBT provides a framework for teaching skills 
related to managing emotions, challenging negative 
thoughts, and problem solving.1 With a combined MET/
CBT intervention, clinicians employ MET during some 
sessions and CBT during others. The MET-focused 
sessions may touch on consequences of substance use, 
reasons for change, and goal setting. The CBT-focused 
sessions may focus on learning refusal skills, finding 
social supports, and planning how to manage emotions.44 
MET/CBT is a psychotherapy that clinicians use alone or 
in conjunction with pharmacotherapy to treat youth and 
young adults with co-occurring disorders.
There is some evidence that combined psychopharmacolgy 
and psychotherapy can be effective for the general adult 
population with co-occurring conditions. Selective 
serotonin reuptake inhibitors (SSRIs), for example, 
have been effective in treating adults for depression 
with co-occurring alcohol use disorder.22-24 For adults 
with co-occurring depression and alcohol dependence, 
antidepressants—which included SSRIs—reduced the 
severity of depression and decreased alcohol use.28 
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While the effectiveness of other medications in youth 
has been documented, the studies included in this 
review evaluated the impact of pharmacotherapy38-43 
and psychotherapy for youth and young adults with 
co-occurring MDD, other depressive disorders, OCD, 
and non-nicotine SUD. The medications (fluoxetine and 
sertraline) examined by the studies cited in this guide 
are approved by the FDA for use with youth under 18 
years old, who have MDD and OCD, respectively. Five 
of the studies assessed fluoxetine,38-40,42-43 and one study 
examined sertraline.41 
In five of the six studies evaluating the impact of 
pharmacotherapy, all study participants received CBT 
or motivational enhancement therapy (MET) combined 
with CBT (also called MET/CBT). Four studies 
included both medication monitoring and therapy 
visits.38-39,41,43 One study provided medication monitoring 
alone, therapy alone, or both.40 One study provided 
medication monitoring visits only and referred patients 
to community- based resources if they were not already 
receiving psychotherapy.42 
Typical Settings
Pharmacotherapy can be administered in a wide range 
of healthcare settings and levels of care. Five studies 
in the current review were conducted at single sites, all 
of which were behavioral health practices at academic 
medical centers.38-39,41-43 One study was conducted at 
multiple sites, including both academic and community 
clinics.40
Diagnosis FDA-approved Medication 
(common brand name)
Age (in years)
Bipolar I disorder 
(acute mania and mixed phases)
Aripiprazole (Abilify) 10 and older
Bipolar I disorder 
(acute mania or mixed phases)
Asenapine (Saphris) 10 and older
Bipolar I disorder 
(depression phase)
Lurasidone (Latuda) 10 and older
Bipolar I disorder 
(depression phase)
Olanzapine and fluoxetine, 
combination drug (Symbyax)
10 and older





Bipolar I disorder 




Bipolar I disorder 
(acute mania, mixed, and maintenance phases)
Lithium ( 
Eskalith, Eskalith CR®, Lithobid®)
12 and older
Bipolar I disorder 




Generalized anxiety disorder Duloxetine (Cymbalta) 7 and older
Major depressive disorder (MDD) Fluoxetine (Prozac) 8 and older
MDD Escitalopram (Lexapro) 12 and older
Obsessive compulsive disorder (OCD) Sertraline (Zoloft) 6 and older
OCD Fluoxetine (Prozac) 7 and older
OCD Fluvoxamine 8 and older
OCD Clomipramine (Anafranil) 10 and older
Opioid use disorder (OUD) Buprenorphine (Subutex, Suboxone) 16 and older
OUD Methadone (Methadose, Dolophine) 18 and older
OUD, alcohol use disorder Naltrexone (ReVia, Vivitrol) 18 and older
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Intensity and Duration of Treatment
A physician or other qualified licensed, healthcare 
provider will determine the appropriate medication, 
dose, and duration of pharmacotherapy for youth 
and young adults with co-occurring mental disorders 
and SUD. These determinations will be specific to 
individuals and include factors such as diagnosis, 
symptom severity, patient preferences, and history of 
treatment response. Pharmacotherapy duration may be 
short- or long-term and should be utilized in combination 
with other treatment. 
General Principles of Management and 
Monitoring 
Especially among youth and young adults, providers 
must monitor individuals for side effects, including by 
laboratory testing. Of specific concern for some but not 
all medications is the possible development of metabolic 
syndrome, clinical worsening, suicidal thoughts and 
behaviors, or unusual changes in behavior by the youth 
and young adult. The best strategy for preventing side 
effects is to maintain close working communication 
between the professional prescribing the medication and 
the patient and guardian so concerns and questions about 
emerging and actual side effects can be discussed and 
addressed.     
Study Demographic Groups
Five reviewed studies included youth and young adults 
aged 12 to 25 at time of treatment entry. In five studies, 
participants had comorbid MDD or other depressive 
disorders and non-nicotine SUD. 38-39,41-43 The sixth study 
included youth with MDD alone and assessed SUD at 
follow-up.40 
Two of the studies had slightly more female participants 
than males,39-40 while the other four studies had more 
male participants than female.38,41-43 Participants were 
predominantly White.39-43 
Generally, individuals were excluded if they had:
•	 Cognitive impairment
•	 Diagnosis of bipolar disorder, schizophrenia, or 
schizoaffective disorder
•	 Significant physical health conditions 
One study excluded individuals with current substance 
use disorder at baseline, but examined substance use 
outcomes at follow-up.40
Clinician Types
Physicians or other qualified healthcare clinicians 
prescribe and monitor pharmacotherapy. In the research 
studies included in this review, a physician (including 
psychiatrists), a pharmacotherapist, or a research nurse 
monitored medication.  
OUTCOMES ASSOCIATED WITH PHARMACOTHERAPY
Reviewed studies demonstrated that all participants receiving pharmacotherapy and the CBT or MET/CBT 
showed improvements in depression symptomology and substance use.38-42 One significant randomized 
controlled trial demonstrated that use of pharmacotherapy with youth and young adults who have co-occurring 
depression and SUD (primarily alcohol and marijuana use disorders) was associated with a significant reduction 
in symptoms of depression beyond treatment as usual (CBT or MET/CBT); there was no significant reduction in 
substance use. Depression was assessed immediately post treatment.42 In another study, participants receiving 
pharmacotherapy alone were compared with those receiving a pill placebo, CBT, or pharmacotherapy and CBT 
combined. There was no difference among the groups in substance use at follow-up.43 
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Review Rating Moderate Evidence for  
Casual Impact
Moderate Evidence for  
Casual Impact
Moderate Evidence for  
Casual Impact
Description Provides a framework 
for teaching skills related 
to managing emotions, 
challenging negative thoughts, 
and problem solving.
A discipline within psychotherapy 
and counseling that engages 
an individual’s family members 
(e.g., parents, siblings, and other 
caregivers) in therapeutic sessions 
and treatment planning.
Refers to medications approved 
by the FDA to treat a youth’s or 
young adult’s mental disorder.
Settings Integrated outpatient Community-based Single site, behavioral health 
practices at academic medical 
center and multiple sites, in both 
academic and community clinics 
Diagnoses Major depressive disorder and 
comorbid alcohol use disorder 
or cannabis use disorder; 
suicidal ideation and comorbid 
substance-related disorder
Mental disorder (unspecified) and 
SUD
Major depressive disorder and/
or comorbid SUD, cannabis use 




Demographically diverse study 
sample; aged 11 to 20
Predominately Black, non-White 
Hispanic, males; aged 17 to 20
Predominately White; aged 12 
to 25
Clinician Types Master’s and PhD-level 
clinicians; psychiatrists 








12 to 33 weekly or biweekly 
sessions in both group and 
individual formats for 3 to 12 
months 
A minimum of weekly sessions 
over four to six months
A combination of medication 
monitoring and therapy visits 
assessing fluoxetine or sertraline 
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Before implementing a treatment practice or program to 
treat youth or young adults with co-occurring disorders, 
it is important to determine whether the intervention 
is appropriate for the particular setting, context, and 
population.
This chapter provides an overview of: 
•	 Factors that organizations and other 
stakeholders must consider prior to and during 
implementation of treatments
•	 Strategies to promote implementation and the 
appropriate adaptation of treatment practices to 
the population of focus
•	 Resources for the treatment practices described 
in Chapter 2
Key Considerations 
When Selecting and 
Implementing Treatment 
Practices to Address Co-
occurring Disorders
The following considerations inform decisions related 
to choosing and implementing interventions to address 
co-occurring serious emotional disturbances (SED/
serious mental illnesses (SMI) and substance misuse, 
and substance use disorders (SUD):
1. Treatment practice selection 
a. Assessing and responding to specific needs 
b. Cultural adaptation and responsiveness 
c. Treatment setting and level of care
d. Assessing fidelity 
2. Funding
3. Training and staffing
4. Coordination of care
5. Treatment engagement, retention, and adherence
6. Relapse prevention and recovery support
Each consideration is described in detail below.
Treatment Practice Selection
Several factors influence treatment practice selection. 
Clinicians should consider the youth’s presenting co-
occurring disorders, symptoms, acuity, culture, and life 
circumstances. Fidelity, which is the extent to which a 
clinician adheres to the core components of the program 
or treatment practice, should be carefully considered 
when adapting a treatment practice based on these 
individual factors. 
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Assessing and Responding to Specific Needs 
Strategies
•	 Compare the effectiveness of interventions in 
treating the individual’s presenting diagnoses. 
For instance, if a youth or young adult has co-
occurring major depressive disorder (MDD) and 
SUD, cognitive behavioral therapy (CBT) is 
likely to be an effective treatment.  
•	 Consider the youth’s readiness to change. CBT 
and motivational enhancement therapy/CBT 
(MET/CBT) can be helpful in engaging youth 
and young adults in treatment, providing them 
with needed self-efficacy, and helping them 
assess their own readiness and motivation to 
change. For example, CBT can be integrated 
with the proven principles of motivational 
interviewing (MI) to improve outcomes. MI is 
a counseling technique and treatment approach 
that helps individuals overcome ambivalent 
feelings and resistance, while clinicians offer 
their empathy and support. In the process, 
individuals become motivated to explore the 
reasons for their behavior with the goal of 
eliciting positive behavioral change.
•	 Examine the youth’s life circumstances, 
developmental stage, and social determinants 
of health. Clinicians should be mindful that 
underlying social determinants of health (e.g., 
food, clothing, housing, safety, and transportation) 
impact the treatment services people receive, 
treatment outcomes, and overall quality of 
life. Clinicians should connect youth to case 
management or other social services whenever 
feasible. Clinicians can screen for and identify 
areas of need using the PRAPARE Toolkit 
(Protocol for Responding to and Assessing 
Patient’s Assets, Risks, and Experiences) 
from the National Association of Community 
Health Centers. Additionally, clinicians need 
to evaluate a youth or young adult’s emotional 
and social developmental stages and provide 
developmentally appropriate interventions.
•	 Assess family influences and characteristics. 
If an underlying cause of a clinical diagnosis is 
related to a family issue, a family-based therapy 
may improve treatment outcomes. Strategies that 
support and enhance the mental health of parents 
and caregivers improve outcomes for youth and 
young adults.1 Family-based therapy recognizes 
that an individual’s symptom management, 
retention in treatment, and overall treatment 
response is shaped not only by individual-level 
factors (e.g., physiology, personal motivation), 
but also by family-level factors (e.g., home 
environment, interpersonal relationships). 
•	 Provide trauma-informed care. Many youth 
and young adults experience a traumatic event 
or live within traumatic circumstances or 
chronic trauma or stress. The Substance Abuse 
and Mental Health Services Administration 
(SAMHSA) has identified four principles that 
ground trauma-informed care:2
	– People at all levels of the organization 
or system have a basic realization about 
trauma and understand how trauma can 
affect families, groups, organizations, and 
communities as well as individuals.
	– People in the organization or system are also 
able to recognize the signs of trauma. 
	– The program, organization, or system 
responds by applying the principles of a 
trauma-informed approach to all areas of 
functioning. 
	– A trauma-informed approach seeks to resist 
re-traumatization of clients as well as staff.
Cultural Adaptation of Treatment Practices
Strategy
•	 If shown to be effective, adapt treatment 
practices to the youth’s cultural values. 
Motivational techniques are adaptable for 
multiple cultures, as the process of change and 
motivational enhancement can be tailored to the 
values, beliefs, and experiences of individuals 
from different ethnic, cultural, and racial 
backgrounds. MI fits well with cultural beliefs of 
the American Indian/Alaska Native community,3 
and there have also been positive results adapting 
MI for Latino immigrants that misuse alcohol.4 
Conditions where people live, learn, work, and 
play that affect their health and wellbeing are 
known as social determinants of health.
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Published articles written by providers who 
have adapted MI are available, documenting 
adaptation of MI to particular populations 
with positive results.4-6 CBT is adaptable to 
multiple cultures using a set of principles to 
guide the changes. Peer-reviewed articles have 
been published on adapting CBT to multiple 
cultures for differing symptoms and disorders. 
This adaptation is known as culturally adapted 
cognitive behavioral therapy (CA-CBT). For 
example, articles are available on adapting 
CBT for Chinese Americans with depression,7 
migrants and ethnic minorities with post-
traumatic stress disorder (PTSD),8 and LGBT 
Latino/a youths and young adults.9 Family-
based therapy (FBT) approaches, predicated on 
connecting with family members and addressing 
negative dynamics and behavioral patterns 
unique to each family system, have also been 
adapted to multiple cultures. For example, 
Familias Unitas is an FBT adapted for Latino/a 
youth at risk for using drugs and their families.10
There is a need for more research and evidence 
on fidelity of treatment practices with diverse 
cultures. Cultural adaptations to treatment 
practices must maintain a careful balance with 
fidelity of the treatment practice.
Treatment Setting and Level of Care 
Strategies
•	  Assess severity of symptoms to determine the 
setting in which services are delivered. Levels 
of care are used to help assign and direct the 
intensity of services appropriate to treat the 
patient. Youth and young adults with less severe 
symptoms may benefit most from outpatient 
care, including care delivered in the primary 
care setting. Inpatient or other intensive modes 
of treatment may be more suitable for youth and 
young adults with severe symptoms. 
Terminology
Pharmacotherapy is the treatment of disease 
through the administration of drugs.11
Psychotherapy involves communication between 
patients and therapists that is intended to help 
people find relief from emotional distress, seek 
solutions to problems in their lives, or modify 
ways of thinking or acting that are preventing 
them from achieving their potential.12 
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•	 Consider treatment history. Clinicians may need 
to try multiple treatments to determine what 
works for a particular individual. Clinicians 
should also determine what specific treatment 
corresponds with the symptoms and severity 
of the disorders; this is particularly critical for 
selection of the appropriate pharmacologic 
option for the youth or young adult. If 
symptoms do not improve with psychotherapy 
methods, adding pharmacotherapy to traditional 
methods may be a route to consider. The 
American Academy of Child & Adolescent 
Psychiatry provides parameters on selecting 
pharmacotherapy options for the treatment of 
bipolar disorder, depression, and anxiety (www.
aacap.org). Pharmacotherapy or combined 
treatments may be best for youth and young 
adults who have not shown improvement 
with psychotherapy alone. Selective serotonin 
reuptake inhibitors (SSRI) are often used to treat 
depression in adults and young adults. Early 
research examining the combined impact of an 
SSRI and MET/CBT shows improvement in 
depression symptoms and reduced substance use 
among recipients when assessed at follow-up.
Assessing Fidelity to the Treatment Practice
Strategies
•	 Carefully balance adaptation with fidelity 
of practice. Fidelity, also referred to as 
adherence, is defined as the extent to which 
the clinician delivering an intervention adheres 
to the protocol or program model intended 
by its developers.13 It is important that 
clinicians always consult training manuals and 
implementation guides for treatment practices 
prior to utilization. While guides may not 
address how to approach youth and young adults 
with co-occurring disorders, clinicians can 
adapt treatment practices while still ensuring 
fidelity to core principles and treatment practice 
components. In some circumstances, adaptation 
may even enhance program or treatment practice 
outcomes. 
Some examples include when:14-15   
	– A treatment practice is tailored to local 
beliefs, languages, or culture to enhance its 
relevance
	– A program component is added
	– Minor modifications are made to a treatment 
practice or program component 
•	 Collect data and evaluate effectiveness. By 
ensuring fidelity to core components when 
making adaptations, not only will clients have 
a better chance at symptom improvement, 
but clinicians implementing these treatment 
practices will be able to better assess their 
impact on symptom reduction. To ensure 
adapted treatment practices are implemented 
with their core elements upheld, it is essential 
to collect data to assess treatment practice 
outcome. When programs are adapted, 
evaluation of the adapted treatment practice tells 
the clinician and program administrator whether 
it has still achieved expected outcomes.
Clinicians and program managers should 
document adaptations made to programs and 
treatment practices along five dimensions: 
•	 Adherence—the extent to which 
program or treatment practice 
components are delivered as intended
•	 Dosage—number of sessions, 
attendance, and frequency and duration 
of sessions
•	 Quality of delivery—the way a program 
or treatment practice is delivered
•	 Participant responsiveness—the way 
clients react to or engage in treatment
•	 Program differentiation—the degree 
to which the critical components are 
delivered and distinguishable from each 
other13
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Training and Staffing
It is important for staff to receive training that is 
developmentally appropriate for youth and young 
adults, is trauma-informed, and includes knowledge of 
SED, SMI and SUD. Specific training on co-occurring 
disorder treatment for youth and young adults is still 
in the early stages, and few clinicians specialize in this 
area.16 Program leaders must ensure every clinician has 
received necessary training and fully understand not only 
the underlying tenets of the system, but the guidelines, 
methods, and structure for utilizing a given treatment 
practice with clients. Additionally, supervisors should 
ensure the treatment practice is implemented and used in 
a consistent manner across clinicians (see discussion of 
fidelity above).
Strategy
•	 Provide initial and ongoing training to 
staff. Associations, such as the American 
Psychological Association, provide continuing 
professional education and training on numerous 
topics, including on treating children with co-
occurring disorders. A well-trained workforce 
that has opportunities to expand its knowledge 
and skills is critical.1
Coordination of Care
Co-occurring disorders are complex and best viewed 
through a holistic lens. Family and peer relationships, 
community programs, academic institutions, child 
welfare systems, and the juvenile justice system all play 
a role in health and wellbeing. 
Individuals with SED/SMI and co-occurring substance 
use may also have other challenges affecting their health 
and recovery that must be addressed (e.g., learning 
disorders, chronic health conditions, poverty, housing 
instability, educational challenges, legal challenges, 
domestic violence). Multiple complex factors contribute to 
the development and maintenance of, as well as recovery 
from co-occurring SED/SMI and SUD. Therefore, 
clinicians should take a systems-based approach.
Strategies
•	 Coordinate treatment with needed health-
related social and economic services. Taking 
a comprehensive, person-centered approach, 
clinicians need to coordinate the client’s 
treatment with their health-related social and 
economic needs obtained from clinicians in 
other systems. Care should be coordinated 
across the complex healthcare and social service 
systems within the client’s community.
•	 Connect physical, mental, substance use, and 
social service providers. A systems-based, 
coordinated, cross-sector approach to care can 
help youth and young adults overcome health-
related social determinants that impact the 
success of services and overall health outcomes.
Treatment Engagement, Retention, and 
Adherence
Youth and young adults with co-occurring disorders 
can be difficult to engage and retain in treatment due 
to factors like peer pressure, shifts in autonomy, and 
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decision-making in young adulthood.17 Engaging 
youth and young adults is critical to achieving long-
term changes. The early stages of therapy are often the 
most important for youth engagement, especially if 
the individual did not seek therapy on his or her own. 
Additionally, logistical and resource concerns like 
transportation and insurance instability can be major 
barriers to treatment initiation and retention.
Strategies
•	 Incorporate engagement goals in clients’ 
treatment plans. To promote engagement and 
adherence throughout the treatment process, 
goal setting and treatment planning should be a 
collaborative process and tied to the individual’s 
own objectives. The goals of therapy should be 
meaningful and tied to long-term aspirations. 
Smaller goals should be built into the treatment 
plan that are realistic and attainable.18 Setting 
and continually reviewing progress on goals and 
the treatment plan can enhance motivation while 
allowing the clinician to assess the level of client 
engagement throughout the treatment process.17
•	 Utilize MI or other brief approaches to 
heighten motivation and increase self-efficacy. 
Clinicians can use MI to help engage clients in 
treatment at the outset. They can also use it in 
combination with other treatments, such as CBT, 
to enhance retention and adherence throughout 
the treatment process.19-20
•	 Strengthen relationships between the clinician, 
client, and families. Therapeutic alliance, or 
the way in which people connect, behave, and 
engage with the therapist, is a strong predictor of 
retention in treatment. Family therapists may be 
able to increase family engagement in treatment 
by building relationships with family members, 
educating them on the treatment practices being 
used, and encouraging positive relationship-
building within the family.21
•	 Identify barriers to treatment and provide 
resources to finish treatment. Completing 
a treatment protocol is integral to successful 
recovery. While engagement in treatment may be 
the most obvious factor, there are several other 
factors that impact whether youth can complete 
treatment. Transportation to appointments, 
parental/guardian support, school attendance, 
stable housing, and health insurance are all 
important factors for treatment completion. 
Clinicians should be aware of the potential 
barriers youth face and assist with resources and 
flexibility when possible. 
Relapse Prevention and Recovery Support
Individuals with co-occurring disorders have higher 
rates of substance use relapse than those with SUD 
alone.22 Youth and young adults typically have fewer 
coping mechanisms and are more impulsive than adults. 
Recovery supports are therefore an important post-
treatment component. Those attending post-treatment 
programs involving case management and community 
reinforcement were more likely to remain abstinent from 
alcohol and marijuana use at three-month follow-up.23
Strategies
•	 Equip youth with the tools and skills needed to 
prevent relapse and support recovery. Because 
youth and young adults are more likely to make 
risky and impulsive decisions, incorporating 
the development of healthy coping mechanisms 
into treatment is important. Clinicians should 
put long-term recovery resources and support 
systems in place prior to treatment completion. 
CBT provides tools that help individuals 
understand triggers for substance use and 
identify healthy ways of coping. These skills 
assist youth beyond the length of treatment.
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•	 Provide recovery support services. Youth and 
young adults who participate in an aftercare 
program receive additional support services in 
the community, and case managers within these 
programs can identify if or when a client may be 
at risk for relapse and refer them to other helpful 
services or their treatment provider.  
•	 Engage families. Families can play a crucial 
role in aiding youth in recovery by providing a 
support system. The Partnership for Drug-Free 
Kids hosts many support groups, continuing 
education programs, and other resources for 
parents of youth with SUD.
Treatment Practice 
Resources
In addition to the introductory, overarching 
implementation guidance provided above, there are 
several manuals and resources developed specifically 
to help stakeholders implement the treatment practices 
described in Chapter 2. Please note that this guide is 
not intended to be a training manual, but additional 
resources are available to support implementation of 
these treatment practices.
Resources for Family Members
The Partnership for Drug-Free Kids provides a 
compendium of resources for parents of youth with 
SUD and related mental health issues, as well as online 
trainings and support groups. 
The Child Mind Institute and Partnership for Drug-Free 
Kids developed a parent’s guide to recognizing and 
addressing co-occurring SUD in their teens and young 
adults.  
Treatment of Co-occurring Disorders 
Resources
SAMHSA’s TIP 42: Substance Use Treatment for 
Persons With Co-Occurring Disorders provides addiction 
counselors and other clinicians, supervisors, and 
administrators with the latest science in the screening, 
assessment, diagnosis, and management of co-occurring 
disorders.
Cognitive Behavioral Therapy (CBT) 
Resources
The Academy of Cognitive and Behavioral Therapies 
provides resources for both clinicians and patients, 
including a therapist search tool, a list of training 
programs (both in-person and virtual), information on 
clinician certification, and a guide to serving children 
and youth. Training and consultation are available to 
assist those implementing CBT.
The Beck Institute offers online training courses, 
information about in-person workshops, blogs, 
resources, and live assistance with program 
implementation, utilizing supervision, and consultation.
The Computer Based Training for Cognitive Behavioral 
Therapy (CBT4CBT) is a self-guided, web-based 
program developed by a team of researchers and 
clinicians at Yale University that uses interactive 
exercises and videos to guide users through seven 
lessons. It can be accessed through clinician or patient 
log-in. It is available in both English and Spanish and the 
CBT toolkit is available for purchase.
The developers of I-CBT provide guidance on how to 
select treatment candidates for I-CBT, and a case study 
example of how to implement I-CBT in the following 
2019 book chapter: Esposito-Smythers, C., Spirito, A., & 
Wolff, J. (2019). CBT for co-occurring suicidal behavior 
and substance use (I-CBT). In M. Berk (Ed.) Evidence-
Based Treatment Approaches for Suicidal Adolescents: 
Translating Science into Practice. Arlington, VA: 
American Psychiatric Publishing. 
SAMHSA’s Mental Health Technology Transfer Center 
Network provides CBT guidelines, training manuals, 
toolkits, workbooks, and training modules, as well 
as resources for implementing CBT with specific 
populations and for specific applications (e.g., SUD, 
anger management, mental health issues). The resources 
are available in multiple languages, including Spanish 
and Chinese.
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Multidimensional Family Therapy 
Resources
MDFT International’s webpage offers treatment manuals 
and videos, training opportunities, and information about 
implementing MDFT in Spanish and French. It provides 
initial and ongoing support to those implementing 
MDFT in substance abuse, mental health, juvenile 
justice, and child welfare practice settings available 
through the organization. 
The National Institute of Justice’s clearinghouse of 
MDFT programs and treatment practices includes 
descriptions, outcomes, and implementation information, 
as well as a rating of the supporting evidence.
Pharmacotherapy Resources
The Food and Drug Administration’s Suicidality 
in Children and Adolescents Being Treated With 
Antidepressant Medications’ webpage describes the 
warning to clinicians and consumers about the increased 
risk of suicidal thinking and behavior in children and 
youth that must be included on the labeling for all 
antidepressant drugs.
SAMHSA’s General Principles for the Use of 
Pharmacological Agents to Treat Individuals with Co-
occurring Mental and Substance Use Disorders outlines 
principles of use. It is designed primarily for clinicians 
who prescribe medication for adults with co-occurring 
mental and substance use disorders and those working 
in administrative and leadership roles in programs or 
agencies that serve adults with co-occurring disorders.
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Examples of Treatment 
Programs
This chapter highlights five examples of programs that 
provide treatment and support to youth and young adults 
with serious emotional disturbances (SED)/serious 
mental illnesses (SMI) and co-occurring substance use or 
substance use disorders (SUD). Each program uses one 
or more of the treatment practices detailed in Chapter 2: 
•	 Cognitive behavioral therapy (CBT)
•	 Multidimensional family therapy
•	 Pharmacotherapy
The chapter describes how each program has incorporated 
these treatment practices as part of a comprehensive 
strategy to address the needs of their populations. 
Programs should implement treatment practices with 
fidelity to evaluated models. Fidelity is the degree 
to which a program delivers a treatment practice as 
intended and must be maintained for desired therapy 
outcomes; however, many programs adapt chosen 
treatment practices to better serve their clients. As 
clinicians modify these treatment practices to address the 
needs and constraints of their population, budget, setting, 
and other local factors, fidelity to the treatment practice’s 
foundational principles and core components is essential. 
The programs in this chapter were identified through 
reviewing the literature, scanning community programs, 
and consulting with experts. The programs implement 
treatment practices with documented evidence of success 
(see Chapter 2), target youth and young adults with a 
range of mental health and substance use problems, and 
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serve geographically, racially, and ethnically diverse 
populations. The programs have not been subject to 
rigorous evaluation of effectiveness and are offered here 
only as implementation examples.
To be included in this chapter, programs had to: 
•	 Implement one or more of the treatment 
practices identified in Chapter 2
•	 Be replicable (well-defined with guidance 
materials or a manual)
•	 Provide appropriate and effective interventions 
for their particular geographic area, treatment 
practice setting, and population
Whenever possible, programs were chosen for inclusion 
that have findings to support their impact on SED/SMI 
and co-occurring substance use or SUD. 
The summaries include information gathered through 
interviews with each program and other program 
materials (print or online). Each summary concludes 
with lessons learned that clinicians shared during the 
interview.
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Established in 2017, Bradley Hospital’s Co-occurring 
Disorders Program (CDP) is an intensive outpatient 
program (IOP) for youth with co-occurring mental health 
and substance use issues. The program typically serves 
10 youth at a time. Some are referred from a higher level 
of care (e.g., emergency department, inpatient treatment), 
while others are referred by parents or pediatricians. 
Participants range in age from 13 to 18, with an average 
age of 16. They are 63 percent male, and 79 percent are 
White, 10 percent are Black/African American, and 10 
percent are Hispanic. Participants commonly present with 
depression or anxiety. Most have issues with alcohol or 
marijuana use, though some are primarily using other 
drugs (e.g., benzodiazepines, inhalants, or opioids). Many 
also have a history of trauma.
The program provides 9 hours of direct service each week 
(3 hours of care, 3 afternoons per week), which provides 
youth with intensive treatment while affording the ability 
to participate in school. Each week, services include: 
•	 Skills-based group therapy that integrates 
dialectical behavior therapy (DBT) and 
mindfulness
•	 Two individual therapy sessions
•	 At least 1 hour of family therapy
•	 Medication monitoring, as needed
Depending on individual treatment needs, participants 
may also meet with a nurse to address additional clinical 
issues. Other components include school consultation, 
case management, psychoeducational programming, and 
health promotion.
Group therapy sessions are skills-driven, and employ 
equal parts motivational enhancement therapy 
(MET) and cognitive behavioral therapy (CBT). 
Multidimensional family therapy (MDFT) is provided 
to improve family communication, functioning, problem 
solving, and emotion regulation, set clear expectations 
and consequences (good and bad), address school-based 
functioning, and keep youth out of the legal system (or 
help them get out). Substance use monitoring is part of 
treatment. 
Model Features and Elements
•	 Group, individual, and family therapy using 
manualized treatments, including CBT, MET/
CBT, and motivational interviewing (MI)
•	 Fully integrated multidisciplinary team including 
a child psychiatrist, clinical psychologists, 
nurses, and a master’s level clinician
•	 Substance use monitoring, including youth self-
report, parent report, and at least weekly urine 
toxicology tests 
•	 Treatment fidelity assessed through:
	– Live supervision of group, individual, 
and family therapy sessions by clinical 
psychologists who specialize in this 
population and these treatment modalities
Treatment Practice Implemented by the 
Program 
Pharmacotherapy, Multidimensional Family 
Therapy (MDFT)
Setting
Intensive outpatient program at a psychiatric 
hospital for children and adolescents.
Population of Focus 
Adolescents who have mental health and 
substance use issues.
Program Duration
Typically about 8 weeks, but varies depending on 




•	 Treatment practice selection: 
Treatment setting 
•	 Coordination of care
Co-occurring Disorders Program
Bradley Hospital (Providence, RI) 
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	– Supervising clinical psychologists reviewing 
recordings of individual and family therapy 
sessions (a minimum of 2 hours of group 
supervision and 30 minutes of individual 
supervision are conducted each week)
•	 Warm hand-off to traditional outpatient (Wave 
Clinic, described in inset) upon program 
completion
Findings and Outcomes 
Upon program completion, youth and young adults show: 
•	 Reduced substance use (nearly 100 percent 
abstinent) 
•	 Improved psychological/mental health 
functioning using validated instruments
•	 Improved school functioning using validated 
instruments
•	 Improved family functioning using validated 
instruments
Lessons Learned 
•	 Take an integrated approach that 
employs comprehensive supports, 
based on individual needs 
•	 Use evidence-based approaches with fidelity 
•	 Ensure individuals do not “fall through the 
cracks” when transitioning from intensive 
outpatient services to less intensive services 
THE WAVE CLINIC 
The Wave Clinic at Bradley Hospital is an 
outpatient program serving adolescents with co-
occurring mental health and substance use issues. 
It was developed in 2018 to provide continuity of 
care for youth who were stepping down from the 
hospital’s Co-occurring Disorders Program, but 
also receives referrals from other IOPs or intensive 
in-home services, the court system, the school 
system, pediatric providers, and inpatient settings.
The clinic sees youth with a variety of internalizing 
and externalizing disorders who also misuse 
substances, most commonly alcohol and 
marijuana. Using evidence-based practices and a 
family-based approach, clinicians see youth once 
or twice weekly. Sessions may be individual, family, 
or parent-only, depending on need. Most treatment 
employs MET/CBT. 
Clinicians monitor the youth’s progress in meeting 
treatment goals using measures of behavior 
and motivation to change and employ toxicology 
screening. As youth make progress, clinicians 
may titrate treatment (e.g., going from once 
weekly treatment to twice a month). To prepare for 
the youth’s transition out of treatment, clinicians 
work with the youth and family to access recovery 
supports and develop a plan for if they experience 
symptoms that might require a return to treatment.
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Encompass is an evidence-based, outpatient treatment 
program for youth and young adults with substance 
use disorders and co-occurring mental health issues. A 
clinical research team at the University of Colorado’s 
School of Medicine created Encompass in 2010 and 
2011. The program has expanded to other sites in 
Colorado, Indiana, and Kentucky. 
The Encompass team treats individuals with cannabis 
and alcohol misuse who have co-occurring depression, 
anxiety, attention-deficit disorder, conduct disorder, 
and other mental health issues. They also treat nicotine 
addiction and vaping. Participants are referred by 
parents, schools, mental health clinics, primary care 
pediatric clinics, family medicine, adolescent medicine 
clinics, substance use treatment programs that do not 
have expertise in co-occurring disorders, juvenile 
justice, college/university mental health clinics, or self-
referrals. 
An estimated 2,500 youth and young adults have 
received the Encompass intervention across all sites in 
all states. Participants are aged 12 to 29 with an average 
age of 17. Most are male (75 percent); 62 percent are 
White, 23 percent are Black/African American, and 15 
percent are other races.
Encompass uses MET/CBT along with contingency 
management (CM; a behavioral reinforcement 
technique) and pharmacotherapy to reduce substance use 
and psychiatric symptoms. 
Treatment consists of 16 weekly, individual sessions in 
a broad range of treatment settings, including outpatient 
mental health settings, school-based settings, primary 
care, and telehealth. A clinician assesses substance 
use and mental health symptoms monthly to evaluate 
responses to treatment and works with a broad team to 
provide an individualized level of care. Pharmacotherapy 
may be incorporated after the first month if the 
co-occurring psychiatric symptom severity is not 
responding to MET/CBT alone. 
The core treatment team meets regularly (weekly 
or monthly) and consists of master’s level licensed 
clinical social workers, doctoral-level psychologists, 
a medical doctor (MD), a doctor of osteopathy (DO), 
and registered nurse practitioners (RNP) trained in the 
Encompass intervention. This team links with an MD, 
DO, or RNP familiar with the Encompass treatment 
model who can perform medication evaluations and 
prescribe medication as clinically indicated. The 
Encompass-affiliated MD/DO/RNP does not have to 
attend the regular team meetings; however, affiliated 
staff must be familiar with the Encompass model and 
clinical measures the team is tracking (e.g., Patient 
Encompass: Integrated Mental Health/Substance 
Treatment
University of Colorado School of Medicine, Department of Psychiatry, Division of Addiction Science, Prevention 
and Treatment (Aurora, CO) 




Outpatient program located within the Department 
of Psychiatry outpatient clinic at University 
Hospital.
Population of Focus 
Youth and young adults with substance use 
disorders and co-occurring mental health issues.
Program Duration






•	  Treatment practice selection: Assessment, 
Fidelity
•	 Training and staffing
•	 Treatment engagement
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Health Questionnaire-9 [PHQ-9], Generalized Anxiety 
Disorder 7-item scale [GAD 7], Attention-Deficit/ 
Hyperactivity Disorder Rating Scale [ADHD-RS]) so 
they can monitor treatment response. They must also be 
aware of medications shown to be safe and effective in 
non-abstinent youth with co-occurring disorders (based 
on randomized control trials). 
Encompass therapists receive weekly case-driven 
clinical supervision in their first year, twice monthly 
clinical supervision in the second year, and monthly 
clinical supervision thereafter. The Encompass 
developer, Dr. Paula Riggs, and the Encompass 
consulting team lead clinical supervision activities. In 
the first year following training, Encompass therapists 
submit one digital audio recorded MET/CBT session 
fidelity/adherence review by the Encompass consulting 
team. Therapists who score below the fidelity/adherence 
threshold receive additional clinical supervision until 
they are in an acceptable rating range. 
 Model Features and Elements
•	 Semi-structured interview at baseline to identify 
co-occurring diagnoses
•	 Manual-driven MET/CBT in weekly individual 
sessions
•	 CM to reinforce abstinence, treatment 
adherence, and prosocial activities
•	 Pharmacotherapy provided as clinically 
indicated
•	 Validated tools to measure psychiatric symptoms 
at baseline and throughout treatment (e.g., PHQ-9 
for depression, GAD-7 for anxiety)
•	 Weekly substance use monitoring (urine 
toxicology screening and timeline follow-back)
Findings and Outcomes 
•	 Around 70 percent completion rate of the 
Encompass program
•	 Over 90 percent compliance with weekly MET/
CBT sessions
•	 Reductions in symptoms of psychiatric 
diagnoses using validated instruments
•	 Reductions in substance use using validated 
instruments
•	 Reduction in psychiatric symptoms often 
associated with reduced substance use and vice 
versa 
Lessons Learned 
•	 Understand that symptoms of a 
co-occurring mental disorder may 
be triggering substance use, and be 
attentive to these internal triggers
•	 Be thoughtful in medication use; Encompass 
focuses on teaching skills and coping strategies 
associated with internal triggers that are often 
symptoms of co-occurring mental disorders, 
so substance and psychiatric symptoms may 
both decline without the need for additional 
pharmacotherapy 
•	 Add CM to MET/CBT to increase treatment 
effectiveness
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The Seminole Tribe of Florida’s (STOF’s) Health and 
Human Services’ Center for Behavioral Health (CBH) 
provides a broad array of integrated medical and behavioral 
health services. The STOF’s Native Connections is an 
outpatient initiative that aims to reduce and prevent suicidal 
behavior and substance use, reduce the impact of trauma, 
and promote mental health among youth and young adults 
up to 24 years of age, using culturally- and trauma-informed 
treatment services. The initiative is funded by SAMHSA as 
part of its Native Connections 5-year grant program, which 
currently serves 148 grantees nationally, including STOF. 
STOF was awarded its grant in 2019.
The Big Cypress Reservation headquarters the program 
with clinical teams of child therapists, mental health 
counselors, and clinical supervisors operating in multiple 
locations across STOF CBH’s catchment area including 
administrative offices in Hollywood, FL. The program 
has clinical teams on five STOF reservations – Big 
Cypress, Hollywood, Brighton, Immokalee, and Tampa.
STOF Native Connections clinicians use CBT, MET, 
MI, and Dialectical Behavior Therapy (DBT) to increase 
protective factors against substance use and suicide. In 
its work, the STOF Native Connections team coordinates 
closely with Tribal Members and community leaders. 
Tribal members can access clinical staff 24 hours a 
day via an on-call system, enabling them to respond to 
mental health and substance use crises.
STOF CBH identifies youth and young adults who may 
benefit from the Native Connections program through direct 
outreach (both family/youth- and clinician-initiated), and 
existing referral partnerships with Tribal leaders, local law 
enforcement, emergency response, child welfare, hospitals, 
and schools. STOF CBH receives referrals and triages 
them to appropriate treatment. Tribal members play critical 
roles in each stage of the referral, intake, and treatment 
process. The program leverages existing partnerships 
between Tribal Members and first responders to youth in 
crisis (i.e., emergency medical services, child welfare) to 
engage community leaders in discussions of treatment need, 
relevance, and cultural context.
As part of the pre- and early implementation process, 
STOF Native Connections staff worked closely with an 
advisory board of Tribal Members to gather feedback 
on planned outreach approaches and therapeutic 
programming. Tribal Members expressed interest in 
additional training and focus on trauma and its impacts. 
As a result, STOF Native Connections clinical staff 
completed an online trauma-oriented therapy course 
offered through the Indian Health Service and two 
additional trainings focusing on trauma-informed CBT 
and trauma’s impact across the lifespan.
Native Connections
Seminole Tribe of Florida Health and Human Services, Center for Behavioral Health  
(Big Cypress Reservation, FL)
Treatment Practice Implemented by the 
Program 
Cognitive Behavioral Therapy (CBT)
Setting
Multiple (outpatient clinics and community 
centers, residential youth homes)
Population of Focus 
Youth and young adults with, or at high-risk for, 
developing, mental health disorders and symptoms 
(including suicidality) and substance use
Program Duration
Varies depending on the needs of the individual 




•	 Treatment practice selection
•	 Funding
•	 Training and staffing
•	 Coordination of care
•	 Treatment engagement
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STOF Native Connections aims to serve 30 tribal youth 
each year. Treatment duration, as well as the type of 
clinical practices (CBT, MET, MI), is customized to meet 
the needs of the individual and family. Youth and young 
adults served by the program present with a variety of 
mental health needs, including but not limited to acute 
and post-traumatic stress disorders, major depressive 
disorder, generalized anxiety disorder, oppositional 
defiance disorder, and conduct disorder.  
Model Features and Elements
•	 A doctoral level psychologist with training 
in CBT, MET, and SUD treatment leads the 
program’s multi-site clinical operations 
•	 Clinicians are on site at five reservations, including 
Big Cypress; staff include child therapists, mental 
health counselors, and clinical supervisors
•	 The program maintains an advisory board of 
Tribal Members who provide feedback on 
program areas of focus and cultural competence 
•	 The program’s clinical staff complete additional 
training on trauma-oriented therapy
Findings and Outcomes 
•	 The program’s grant was awarded in May 2019, 
and there were no measurable outcomes as of 
June 2020
•	 Much of the originally planned work has 
been paused or modified due to coronavirus 
(COVID-19)
Lessons Learned 
•	 Keep trauma at the forefront of one’s 
mind when considering an adolescent 
or young adult’s clinical presentation
•	 Understand how trauma may contribute to and 
interact with an individual’s substance use and 
emotional and behavioral issues, and apply a 
trauma-informed approach to service delivery
•	 Leverage existing partnerships with other youth-
serving clinicians, coordinate closely with tribal 
leaders, and deliver services in a culturally 
responsive manner  SAMHSA NATIVE 
CONNECTIONS GRANTS 
Native Connections is a 5-year SAMHSA grant 
program that helps American Indian and Alaska 
Native communities identify and address the 
behavioral health needs of Native youth. The 
Native Connections grant program supports 
grantees in:
•	 Reducing suicidal behavior and substance 
use among Native youth up to age 24
•	 Easing the impacts of substance use, 
mental illness, and trauma in tribal 
communities
•	 Supporting youth as they transition into 
adulthood
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Seasons Center for Behavioral Health (Seasons) is a 
nonprofit behavioral health center that has been serving 
children, youth, and adults in northwest Iowa for over 
60 years. Seasons received a SAMHSA Certified 
Community Behavioral Health Clinic (CCBHC) 
Expansion grant in late 2018 and began enrolling 
participants in its CCHBC in early 2019. Through the 
CCBHC, participants receive wraparound care including 
care coordination, mental health and substance use 
therapy, psychiatric services, Assertive Community 
Treatment teams, peer family support, peer recovery 
support, psychiatric rehabilitation, health and wellness 
coaching, and mobile crisis. 
Individuals presenting with co-occurring mental and 
substance use disorders connect with clinicians trained 
in treating individuals with co-occurring disorders. 
There is one practitioner who is a certified alcohol/drug 
abuse counselor (CADC) and a licensed mental health 
counselor (LMHC); otherwise, care occurs between 
CADCs and LMHCs or licensed independent social 
workers. Typically, co-occurring treatment includes 
MI, CBT, Seeking Safety, and DBT. All clinicians are 
certified at the basic level of at least one evidence-based 
practice, such as MI, DBT, or Seeking Safety.
Seasons has served the community since 1959 and 
is well known, but as the CCBHC model is new to 
the community, the organization started marketing 
the new services provided by the CCBHC. Juvenile 
court, schools, parents, and churches often refer youth 
participants. Seasons serves a rural area that covers 
2,000 square miles and nine counties. Most participants 
are White; 5 percent are Black/African American, 
4 percent are American Indian, and 14 percent are 
Hispanic. Youth and young adult participants are 52 
percent male.
The CCBHC serves youth with co-occurring disorders 
who are aged 13 and older, and as of March 2020, it 
was serving 317 youth. The CCBHC often sees youth 
with mental health issues related to attention-deficit/
hyperactivity disorder, anxiety, depression, autism 
spectrum disorder, or unspecified neurodevelopmental 
disorders, and substance use involving nicotine, alcohol, 
marijuana, and methamphetamines. Clinicians use the 
Substance Abuse Subtle Screening Inventory Fourth 
Edition (SASSI-4) at intake and prior to discharge. 
During treatment, symptoms are re-evaluated every 6 
months through the Alcohol Use Disorders Identification 
Test (AUDIT) screen (as appropriate for the specific 
substance).
Model Features and Elements
•	 Integrated mental health, substance use, and 




•	 Individual therapy with clinician specializing in 
co-occurring disorders treatment 
Seasons Certified Community Behavioral Health Clinic
Seasons Center for Behavioral Health (Spencer, IA)
Treatment Practice Implemented by the 
Program 
Cognitive Behavioral Therapy (CBT)
Setting
Community behavioral health
Population of Focus 
Youth and adults with mental and/or substance use 
disorders
Program Duration
8 to 12 weeks, or longer depending upon 




•	 Treatment practice selection: Cultural 
adaptation and responsiveness
•	 Coordination of care
•	 Relapse prevention/recovery support
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Findings and Outcomes 
•	 Swifter reduction of symptom intensity
•	 Fewer calls from schools to the crisis team
•	 Less extreme and fewer events requiring crisis 
team response at the individual level. 
Lessons Learned 
•	 Be consistent in outreach to 
and communication with other 
organizations serving the 
population (e.g., schools, law 
enforcement, hospitals, YMCAs)
•	 Recognize that stigma is still a significant barrier 
to care among some populations; be patient with 
those who may not be able to explain why they 
need help or what they are experiencing.
SAMHSA CCBHC GRANTS 
CCBHCs provide person- and family-centered 
integrated services. The purpose of SAMHSA’s 
CCBHC Expansion grant program is to increase 
access to and improve the quality of community 
mental and substance use disorder treatment 
services. CCBHCs provide comprehensive 
24/7 access to community-based mental and 
substance use disorder services, including crisis 
services, treatment of co-occurring disorders, and 
physical health care in a single location.
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Nationwide Children’s Hospital is the second largest 
pediatric hospital in the United States, with more than 
1.5 million patient visits each year. A component of 
Nationwide Children’s Hospital’s behavioral health 
specialty is the Treatment for Healthy Alternatives 
Program, which was established in 2010. This program 
serves youth and young adults from Franklin County, 
OH, with substance use and co-occurring mental health 
issues through multiple levels of care. The hospital, 
other clinicians, parents, or the courts usually refer 
youth. Patients have included families from the full 
range of socio-economic backgrounds and nearly every 
neighborhood in the area. In 2019, slightly more than 
half of patients were male (55 percent). Seventy-five 
percent of patients were White, 13 percent were Black/
African American, and 5 percent were bi-racial or multi-
racial. In addition, 8 percent of patients reported being 
Latino or Hispanic.
Treatment for Healthy Alternatives offers an intensive 
home-based program that employs an Integrated Co-
occurring Treatment (ICT) approach to provide services, 
and focuses on youth and young adults with SUD and 
a co-occurring internalizing mental health issue (i.e., 
depression or anxiety). Cannabis is the most common 
substance use diagnosis. Major depressive disorder has 
been the most prevalent co-occurring mental health 
condition among this population, but recently there 
has been an increase in anxiety disorders and trauma. 
Some youth and young adults also have oppositional 
defiant disorder or conduct disorder in addition to an 
internalizing issue. 
In ICT, each clinician spends 3 to 5 hours per week 
working with the youth, family, and/or parents in the 
home. Clinicians use MI throughout treatment and often 
employ CBT. The particular mix of individual, family, 
and/or parent treatment is individualized to each family’s 
needs. Families work with the same clinician throughout 
their time in the program, which is 4 to 6 months. 
Additionally, clinicians may provide case management, 
and depending on family needs, may attend court with 
Treatment for Healthy Alternatives
Nationwide Children’s Hospital (Columbus, OH)
Treatment Practice Implemented by the 
Program 
Cognitive Behavioral Therapy (CBT)
Setting
Pediatric hospital, family home
Population of Focus 
Youth and young adults with substance use and 
co-occurring mental health issues
Program Duration






•	 Training and staffing
•	 Coordination of care
•	 Treatment engagement
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LINKAGE TO OTHER LEVELS OF CARE
Treatment for Healthy Alternatives also provides outpatient care, which was added in 2017 to facilitate step-
down from intensive home-based service. Many youth transition between these levels of care. A co-occurring 
diagnosis is not required to receive outpatient services. 
More recently, the program added a clinician who partners with the medication assisted treatment (MAT) 
program within adolescent medicine. This way, youth or young adults receiving MAT may receive support from a 
behavioral health clinician or be linked with the outpatient program.
the family, coordinate with the school, or identify 
additional resources (e.g., help a caregiver get new 
glasses). Youth and families also have access to a 24/7 
on-call crisis team.
Every clinician at the hospital receives two days of CBT 
training and one day of MI training during new hire 
orientation and may opt to participate in additional CBT 
and MI trainings.  In addition, Treatment for Healthy 
Alternatives clinicians complete quarterly trainings, 
equating to a minimum of 16 hours per year, specific 
to treating youth and young adults with substance use 
and co-occurring mental health issues. ICT clinicians 
complete a 2-day training on intensive home-based 
treatment and participate in fidelity assessments 
administered by the Case Western Reserve University’s 
Center for Innovative Practices. ICT also includes 
weekly consultation; each clinician presents their most 
challenging case to the group for discussion. 
The program began under a federal grant (Bureau of 
Justice Assistance Second Chance grant program) 
focused on youth on parole who were returning home 
from an inpatient treatment or juvenile justice facility. 
After grant completion, the program secured county and 
private funding. The program began serving youth with 
juvenile justice involvement more broadly, and now 
serve any youth in the county needing this level of care.
Model Features and Elements
•	 A mix of individual, family, and/or parent 
treatment for 3 to 5 hours
•	 Clinicians provide treatment, case management, 
and other support, as needed
•	 One clinician stays with the family for the 
duration of treatment
•	 Program provides a direct link between ICT and 
outpatient  
Findings and Outcomes 
•	 Reduced substance use 
•	 Increased safety
•	 Stabilization (e.g., fewer hospitalizations, 
improved school-related outcomes) . 
Lessons Learned 
•	 Take a trauma-informed approach; 
screen and assess for trauma, 
recognize that many clients have 
experienced trauma, and consider 
the impact of trauma on their behaviors and 
symptoms and in response to clients or families 
•	 Be flexible; for example, if the family is 
suffering, it may be appropriate to focus on 
parents/caregivers for a time, or to employ DBT
•	 Manage waitlists appropriately; when people are 
ready for treatment, they are ready right now
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Evaluating a practice or program can provide 
information about how well a practice has been 
implemented, what is and what is not working in a 
program, and how a program or practice benefits clients. 
This information can be helpful in securing funding 
by providing evidence of program effectiveness. In 
addition, stakeholders can use information gathered 
through evaluation to encourage implementation of that 
practice in other programs or communities.
This chapter provides an overview of approaches to 
evaluate both the implementation and effectiveness of 
practices that are designed to treat youth and young adults 
with serious emotional disturbances (SED)/serious mental 
illnesses (SMI) SED/SMI and substance use or substance 
use disorders (SUD). The chapter also includes information 
on implementing a continuous quality improvement (CQI) 
process. The U.S. Department of Health and Human 
Services (HHS) defines CQI as, “the systematic process 
of identifying, describing, and analyzing strengths and 
problems and then testing, implementing, learning from, 
and revising solutions.” CQI is an essential process for 
successfully realizing a practice. Finally, the chapter 
concludes with specific evaluation resources, including 
some suggested measures for potential outcomes to track.
Resources for 
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Types of Evaluations 
There are many stages or types of evaluation: before 
starting a program to determine its feasibility (formative 
evaluation or evaluability assessment), during 
implementation (process evaluation and CQI), and 
after the intervention has been delivered to at least 
one client (outcome and impact evaluations). Each 
type of evaluation is necessary to assess a practice’s or 
program’s effectiveness and fidelity. Fidelity is the extent 
to which a clinician adheres to the core components of 
the program or practice. The graphic below illustrates 
these evaluation types in greater detail.
Preparing to Collect Data
The following steps can help clinics and clinicians 
prepare to collect and analyze data:
•	 Determine if the purpose of the data 
collection is evaluation or research. Qualitative 
and quantitative evaluation and research enables 
managers and clinicians to learn from clients 
and obtain the perspective of those with lived 
experiences. Both evaluation and research 
can also involve collecting data from staff 
who deliver the new treatment to obtain their 
perspective on facilitators and challenges to 
practice implementation. 
Qualitative and quantitative data are 
complementary; each provides critical insight 
into how the intervention is operating and 
achieving the intended objectives. 
•	 Qualitative data include any non-
numeric, text-based information, such 
as verbal, visual, or written data.  
Qualitative data collection methods 
include interviews, focus groups, clinical 
observations, gathering data from 
documents and images, and open-ended 
survey questions and polling responses. 
•	 Quantitative data are numeric data 
that can be processed by mathematical 
or statistical analysis. Quantitative 
data collection includes close-ended 
survey questions and polling responses, 
services and utilization data, and claims 
and encounter data.
Qualitative and quantitative research enables 
managers and clinicians to learn from clients 
and obtain the perspective of those with lived 
experiences.  
Research can also involve collecting data 
from staff who deliver treatment using the new 
practice to obtain their perspective on facilitators 
and challenges to practice implementation.
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USING CONTINUOUS QUALITY IMPROVEMENT (CQI)  
TO IMPROVE PROGRAM IMPLEMENTATION
What is CQI?
CQI involves a systematic process of assessing program or practice application and short-term outcomes and 
then involving program staff in identifying and making improvements in service delivery and organizational 
systems to achieve better treatment outcomes. CQI helps assess practice fidelity, the degree to which a 
program delivers a practice as intended.
CQI differs from process evaluation in that it involves quick assessments of program performance, timely 
identification of problems and potential solutions, and implementation of small improvements to enhance 
treatment quality. CQI is usually conducted by internal staff. Process evaluation involves longer-term 
assessments and is best conducted by an external evaluator.
The Network for Improvement of Addiction Treatment (NIATx), a project originally funded by SAMHSA’s Center 
for Substance Abuse Treatment (CSAT), offers tools to conduct CQI and improve services in substance use 
disorder treatment settings. NIATx is based on the principle of program 
improvement through a series of small changes, tested and applied one at a 
time, that in the end have a cumulative effect.
The Institute for Healthcare Improvement’s PDSA Model for Improvement  
identifies a scientific method for testing small-scale changes and using results 
in an action-oriented, cyclical manner. The stages are: planning it (Plan), 
trying it (Do), observing the results (Study), and acting on what is learned 
(Act). 
Why use CQI? 
CQI takes a broader look at the systems in which programs or practices 
operate. Because of the pivotal role it plays in performance management, 
organizations treating individuals with SED/SMI and co-occurring substance 
use and SUD are encouraged to implement CQI procedures.  
What are the steps involved in CQI?
Although steps in the CQI process may vary based on objectives, typical CQI steps are:
•	 Identify a program or practice issue needing improvement and a target improvement goal
•	 Analyze the issue and its root causes
•	 Develop an action plan to correct the root causes of the problem, including specific actions 
•	 Implement the actions in the action plan
•	 Review the results to confirm that the issue and its root causes have been addressed and short-term 
and long-term treatment outcomes have improved
•	 Repeat these steps to identify and address other issues as they arise
Institute for Healthcare Improvement. (n.d.). Science of Improvement: Testing Changes. 
http://www.ihi.org/resources/Pages/HowtoImprove/ScienceofImprovementTestingChanges.aspx
New Jersey Department of Children and Families. (n.d.). CQI Framework: Five Stages of Continuous Quality Improvement. 
https://www.nj.gov/dcf/about/divisions/opma/CQI%20framework.pdf
NIATx National Program Office. (n.d.). What is NIATx? University of Wisconsin-Madison. 
https://www.niatx.net/what-is-niatx/ 
Office of Adolescent Health. (n.d.). Continuous Quality Improvement, Part 1: Basics for Pregnancy Assistance Fund Programs. 
U.S. Department of Health & Human Services. https://www.hhs.gov/ash/oah/sites/default/files/cqi-intro.pdf
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Program evaluation supports program 
improvement. Evaluation of programs 
implemented in clinical settings contributes 
to generalizable knowledge by implementing 
study protocols and procedures approved by 
Institutional Review Boards (IRB) and that 
adhere to human subjects research protections. 
When designing program evaluations, 
researchers should consult their institutions 
to ensure they are following appropriate data 
collection procedures.
•	 Identify team members to conduct evaluation 
activities. Regardless of the type of evaluation 
conducted, collecting and analyzing data takes 
time. Programs need to identify team members 
who can conduct evaluation activities and secure 
funding to protect their time for evaluation 
trainings, data collection, and data analysis. 
•	 Determine your process and outcomes of 
interest to determine impact and effect. A 
challenging step in implementing new practices 
is to determine whether the practice has yielded 
desired outcomes. An outcome is the change 
a program hopes to accomplish through the 
enactment of a practice. Evaluations and CQI 
efforts use a variety of data to assess the impact 
of interventions. 
Process and Outcome 
Measures to Determine 
Impacts and Effects
While selecting a practice or program, organizations 
should consider evaluation activities. As practices do 
not occur in isolation, consider whether the impact of 
one practice or a combination of practices is effective 
for the population. The table below describes variables 
program managers, clinicians, and others may use to 
evaluate practices identified in Chapter 2. Many of these 
short- and intermediate-term outcomes may be tracked at 
baseline and throughout the practice or program duration 
through electronic health records or qualitative methods. 
Administrative and survey data may provide longer-term 
outcomes.
Illustrative Measure Illustrative Indicators Illustrative Data Sources
Process Measures
Treatment engagement • Extent of client engagement in the 
treatment
• Client self-report
• Social service agency electronic data sources
 Treatment retention • Number of treatment sessions 
attended
• Attendance/administrative data 
• Social service agency electronic data sources
Short-term and Intermediate Outcome Measures
Reduced use of 
substances 
(short- and long-term)
• Amount of use
• Ever used
• Frequency of use
• Usage during specified period (e.g., 
past 30 days, past year)
• Addiction Severity Index (ASI)
• Client self-report
• CRAFFT Interview 
• Columbia Impairment Scale (CIS)
• Lab data (i.e., urine screen)
• Maudsley Addiction Profile (MAP) 
• Substance Problem Scale (SPS) 
• Teen Addiction Severity Index (TASI)
• Timeline Follow-back Method Assessment (TLFB)
Reductions in risky 
behavior
• Attendance in extracurricular or 
athletic activities
• Attendance in school
• Behavioral conduct 
• Curfew compliance
• Effectiveness of parenting practices 
• Reduced use of substances
• Addiction Severity Index (ASI)
• Client self-report
• Disruptive Behaviour Disorder Rating Scale (DBDRS)
• Maudsley Addiction Profile (MAP)
• Parent/guardian observation 
• Parent Practices Questionnaire (PPQ)
• School administrative records 
Evaluations Include a Variety of Process and Outcomes Measures
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Illustrative Measure Illustrative Indicators Illustrative Data Sources
Short-term and Intermediate Outcome Measures
Improvements in 
behavioral, psychiatric, 
health, and emotional 
functioning 
• Attainment of client’s personal goals 
• Decreases in legal involvement
• Improved daily functioning (e.g., 
hygiene, making meals)
• Increased enjoyment of activities
• Improved interest in activities or 
events 
• Improved sleep
• Improved socialization 
• Participation in rehabilitation 
program, school, or employment 
• Participation in medical 
appointments and care
• Remission of mental disorder
• Reduction or absence of suicidal 
ideation and self-harm
• Reduction in feelings of 
helplessness and hopelessness 
• Stable relationships/social functioning
• Client self-report 
• Beck Depression Inventory (BDI-II)
• Child PTSD Symptom Scale (CPSS)
• Employment administrative data
• Hamilton Rating Scale for Depression (HAM-D-27)
• Hospital and medical facility administrative data
• Justice system administrative data 
• Maudsley Addiction Profile (MAP)
• Parent/guardian/friend observation
• Patient Health Questionnaire (PHQ-9)
• Quick Inventory of Depressive Symptomatology 
(QIDS) and Quick Inventory of Depressive 
Symptomatology – Adolescent (QIDS-A)
• School administrative data 
• Strengths and Difficulties Questionnaire
• Youth Self-Report (YSR)-Internalizing Behavior 





• Attainment of client’s personal goals 
for education and professional 
development
• School achievement
• Vocational training 
• Client self-report
• Degree/certificate attainment 
• Employment status 
• Grade promotion/retention
• Graduation or dropout status 
• Overall grade point averages 
• Standardized test scores 
Long-term Outcomes Measures
Reduced prevalence of 
substance use 
• Prevalence of substance use among 
youth and adults
• Large scale national surveys
• National databases 
Reduction in mental 
health issues in 
individuals with 
substance use disorder
Rate of hospitalizations related to: 
• Completed suicides 
• Legal involvement 
• Mental health and substance use 
disorders
• Substance overdoses 
• Client self-report
• Hospital and medical facility administrative data 
• Justice system administrative data
Reduction in co-




• Possession of substances
• Property crimes
• Public impairment  
• Underage smoking or drinking 
• Violent crimes
• Client self-report
• Justice system administrative data
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•	 A Framework for Program Evaluation from the 
Program Performance and Evaluation Office at 
the Centers for Disease Control and Prevention 
summarizes essential elements of program 
evaluation.
•	 The Community Toolbox from Center for 
Community Health and Development at the 
University of Kansas includes a step-by-
step guide to developing an evaluation of 
a community program, specific tools, and 
examples.
Quality Improvement and Continuous 
Performance Monitoring
•	 Institute for Healthcare Improvement’s Quality 
Improvement Essentials Toolkit includes 
the tools and templates to launch a quality 
improvement project and manage performance 
improvement.
Resources for Evaluating Practices 
Involving Youth and Young Adults 
•	 Cognitive Behavioral Therapy (CBT): The 
Beck Institute for Cognitive Behavior Therapy 
provides resources on How to Know if Therapy 
is Working and an assessment on Clinical 
Measures in CBT – A Hassle or a Help?  
•	 Motivational Enhancement Therapy (MET)/
CBT: A National Institute on Drug Abuse 
funded study entitled Development and Initial 
Validation of a Client-Rated MET-CBT 
Adherence Measure details its client-rated MET/
CBT fidelity adherence measure.   
•	 Pharmacotherapy: The Children’s Aggression 
Scale (CAS) was rated moderate in its 
psychometric properties for evaluating efficacy 
of pharmacotherapy interventions in youth.  
•	 Family-Based Therapies: The Family Therapy 
Fidelity and Adherence Check (FBT-FACT) 
showed moderate to strong inter-rater agreement 
for assessing fidelity of family-based therapy in 
a youth population.
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Appendix 2: Evidence Review Methodology 
The authors followed a rigorous, systematic evidence 
review process in the development of this guide. This 
appendix provides an overview of the evidence review 
methodology used to identify the ratings for the practices 
included in the guide:
•	 Cognitive Behavioral Therapy 
•	 Multidimensional Family Therapy 
•	 Pharmacotherapy 
Reviewers, in coordination with SAMHSA and experts, 
conducted a four-step process to select practices, identify 
related studies, review and rate studies, and identify 
practice ratings.
Step 1: Practice Selection 
The authors identified these three practices after a review 
of the literature and in consultation with experts. In an 
effort to include interventions that would be most useful, 
eligible practices were required to meet the following 
criteria for evidence review: 
•	 Be clearly defined and replicable 
•	 Address the target outcome of reducing 
stimulant misuse 
•	 Be currently in use
•	 Have studies of their effectiveness
•	 Have accessible implementation and fidelity 
supports
At the conclusion of this step, SAMHSA and the guide’s 
Expert Panel reviewed the proposed practices identified 
by the authors and agreed on three for inclusion in the 
evidence review and rating process.
Step 2: Study Identification
Once the practices were selected, the reviewers 
conducted a comprehensive review of published 
research on these practices to identify studies of the 
selected practices. This review only included studies 
from eligible sources (i.e., peer reviewed journals and 
government reports) that avoid clear conflicts of interest. 
The reviewers documented all potential studies identified 
through the literature search.
The studies identified in the literature search varied in 
type and rigor, so the reviewers assessed them further 
for inclusion in the evidence review. To be eligible for 
review and study rating, research studies had to: 
•	 Employ a randomized or quasi-experimental 
design, or 
•	 Be a single sample pre-post design or 
an epidemiological study with a strong 
counterfactual—a study that analyzes what would 
have happened in the absence of the intervention. 
Literature reviews, descriptive studies, implementation 
studies, and meta-analyses were not included in the 
review, but were documented to provide context and 
identify implementation supports for the practices.
Additionally, to be eligible for further review and rating, 
studies had to:
•	 Be published or prepared in or after 2000
•	 Be a publicly available peer-reviewed or 
research report
•	 Be available in English
•	 Include at least one eligible outcome related to 
the topic
•	 Have a comparison/control group that is 
treatment as usual or no/minimal intervention 
if using a randomized experimental or quasi-
experimental designs
Step 3: Study Review and 
Rating
Next, trained reviewers assessed each study to ensure 
the methodology was rigorous and therefore could 
demonstrate causation between the practice and 
the identified outcomes. Reviewers reviewed and 
documented each study to ensure that: 
•	 Experimental and comparison groups were 
statistically equivalent, with the only difference 
being that participants in the experimental 
group received the intervention and those in the 
comparison group received treatment as usual or 
no/minimal intervention 
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•	 For randomized experiments with high attrition 
and for quasi-experimental designs, baseline 
equivalence was established between the 
treatment and comparison groups 
•	 For randomized experiments, randomization 
was not compromised. For example, ensuring 
that reassignment of treatment status, usually 
made to balance the distribution of background 
variables between treatment and control groups, 
did not occur.
•	 Study did not have any confounding factors 
(factors that affect the outcome but are not 
accounted for by the study).
•	 Missing data were addressed appropriately
	– Imputation based on surrounding cases was 
considered valid 
	– Complete case analysis was considered valid 
and accounted for as attrition 
	– Using model with dummy for missing as a 
covariate was considered valid 
	– Assuming all missing data points are either 
positive or negative was not considered 
valid 
	– Regression-based imputation was considered 
valid, mean imputation was not considered 
valid
•	 Outcome measures were reliable, valid, and 
collected consistently from all participants
•	 Valid statistical models were used to estimate 
impacts
•	 Practice demonstrated improved outcomes 
Based on the study design and these study 
characteristics, reviewers gave each study a rating for 
causal impact. Reviewers used the following scoring 
metric for each study based on the eight factors above to 
determine if a study is rated:
•	 High support of causal evidence
•	 Moderate support of causal evidence
•	 Low support of causal evidence
Only randomized controlled trials, quasi-experimental 
designs, and epidemiological studies with a strong 
comparison were eligible to receive a high or moderate 
study rating. 
Step 4: Practice Rating
After all studies for a practice were assessed for these 
criteria, the reviewers gave each practice a rating 
based on the number of studies with strong, moderate, 
or emerging support of causal impact. Causal impact is 
evidence demonstrating that an intervention causes, or 
is responsible for, the outcome measured in the study’s 
sample population. The practice was placed into one 
of the following categories based on the level of causal 
evidence of its studies:
•	 Strong Evidence: Causal impact demonstrated 
by at least two randomized controlled trials, 
quasi-experimental designs, or epidemiological 
studies with a high or moderate rating.
•	 Moderate Evidence: Causal impact 
demonstrated by at least one randomized 
controlled trial, quasi-experimental design, or 
epidemiological study with a high or moderate 
rating.
•	 Emerging Evidence: No study received a high 
or a moderate rating. The practice may have 
been evaluated with less rigorous studies (e.g., 
pre-post designs) that demonstrate an association 
between the practice and positive outcomes, but 
additional studies are needed to establish causal 
impact.
The four-step process described above resulted in 
identification and rating of three practices. The rating 
given to each practice is intended to inform decision 
making about adoption of new practices or clinical or 
system enhancements that will improve outcomes for 
affected individuals.
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